Written and medically reviewed by: Assoc. Prof. Cengiz Dibekoğlu, MD, General SurgeryLast updated:
Hereditary Cancers — Hereditary Cancer Overview
Clues, sequencing, and how this links to molecular testing
Hereditary-cancer concern is a planning topic, not a panic topic. Clinical history and tumor features come first; genetic counseling and germline testing follow when the question is clear. Most patients do not have a hereditary syndrome — clarifying early still protects families when risk is real.
Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.
© Cengiz Dibekoğlu — illustrative; not for unauthorized use
Figure summary
This educational figure shows: Overview.
Who may be a candidate?
- Patients with young-onset or multiple cancers
- Families with related cancers across generations
- International patients preparing a structured second-opinion visit
Possible advantages
- Separates tumor biomarkers from germline risk testing
- Explains why emergency surgery is not delayed for every panel
- Links to Lynch, BRCA, and counseling chapters
Limits & realistic expectations
- Cannot replace genetic counseling or laboratory reports
- Local protocols refine which panels are offered
- A negative germline test does not erase all clinical risk
Key points
Clinical clues
Young-onset colorectal or breast cancer, bilateral disease, male breast cancer, endometrial plus colon history, or a strong family history are reasons to ask — not automatic diagnoses.
Which test first?
In colorectal cancer, MMR/MSI is often an early step when guidelines support it. Breast cancer frameworks increasingly offer BRCA1/2 to many patients ≤65. Pancreatic adenocarcinoma usually includes a germline testing discussion for most patients, with counseling and consent.
- Key note inside
Emergencies vs elective genetics
Necessary emergency surgery proceeds; germline and many systemic choices can follow when results return.
- Key note inside
Important
This page is for education. It is not medical advice and does not replace a visit with your physician.
Frequently asked questions
Does every cancer need germline testing?
No. Testing should answer a concrete treatment or family-risk question.
Is tumor MMR the same as Lynch diagnosis?
No. dMMR/MSI-H opens evaluation; germline confirmation needs counseling and dedicated testing.
Will genetics delay emergency surgery?
Emergency care for obstruction, perforation, or sepsis is not postponed solely for panels.
More chapters in this hub
Lynch Syndrome
MMR/MSI, colorectal risk, and family screening
BRCA and Familial Breast Risk
Who is offered testing; surgery and surveillance frame
FAP
Polyposis, APC, and surgical timing
MUTYH and Serrated Polyposis
MAP, serrated pathway, and surveillance intervals
CDH1
Hereditary diffuse gastric cancer risk
Li-Fraumeni Syndrome
TP53 and multi-cancer spectrum
Peutz–Jeghers Syndrome
Hamartomatous polyps and surveillance
Genetic Counseling
Consent, results, and talking with relatives
Molecular Testing in Cancer
Organ-specific biomarkers that often open this conversation
Appointment / info
This page is for education. It is not medical advice and does not replace a visit with your physician.
Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.